Performance and clinical decision-making using the prognostic 40-gene expression profile (40-GEP) test in 1,018 patients with high-risk cutaneous squamous cell carcinoma (SCC)

Jennifer J Siegel, Anesh Prasai, Aaron S Farberg, Matthew S Goldberg
2022 SKIN The Journal of Cutaneous Medicine  
This study was sponsored by Castle Biosciences, Inc. (CBI), which provided funding to the contributing centers for tissue and clinical data retrieval. JJS, AP, and MSG are employees and options holders of CBI. ASF is a consultant for CBI. 40-GEP Risk Class Overall Cohort 3-year MFS (95% CI) Overall Event Rate Univariate Cox regression analysis (HR) Class 1 95.3% (93.6-97.0%) 5.1% 1 Class 2A 81.9% (78.2-85.8%) 18.8% 4.0 Class 2B 56.9% (44.8-72.2%) 43.1% 11.4 Without 40-GEP 88.2% (86.3-90.2%) 12.3% --Methods
doi:10.25251/skin.6.supp.96 fatcat:etrkvmu3ezc2toau3imtbklv7u